Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Sees R&D Rebound, Says FDA Safety Reviews “Not Inappropriate”

Executive Summary

Refinements to pharmaceutical industry pipelines during the Clinton healthcare reform era are about to pay off in a wave of new product launches, Pfizer CEO Hank McKinnell told investors at the Bear Stearns healthcare conference in New York City Sept. 17

You may also be interested in...



FDA Is “Conservative” On Safety, But “Appropriately So,” Pfizer Says

The ongoing discussions between FDA and Pfizer over Lyrica (pregabalin) undercut the argument that the agency is too soft on industry, Pfizer Worldwide Development President Joe Feczko suggested during a Nov. 30 analyst meeting in Groton, Conn

FDA Is “Conservative” On Safety, But “Appropriately So,” Pfizer Says

The ongoing discussions between FDA and Pfizer over Lyrica (pregabalin) undercut the argument that the agency is too soft on industry, Pfizer Worldwide Development President Joe Feczko suggested during a Nov. 30 analyst meeting in Groton, Conn

Pfizer Stops Swinging For The Fences; Combo Products Are Big Opportunity

Pfizer is investing more heavily in low-risk "product enhancements" to help round out its R&D portfolio

Related Content

UsernamePublicRestriction

Register

PS040516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel